Observational studies and clinical trials of menopausal hormone therapy: Can they both be right?

Menopause

Volumn 13, Issue 1, 2006, Pages 1-3

  Allison, Matthew A ^a   Manson, JoAnn E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ESTROGEN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; PLACEBO; PROTHROMBIN;

CLINICAL OBSERVATION; EDITORIAL; FEMALE; HEART INFARCTION; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; STROKE; VASOMOTOR REFLEX; VENOUS THROMBOEMBOLISM; ADULT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; METHODOLOGY; MIDDLE AGED; NOTE; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; WOMEN'S HEALTH;

ADULT; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OBSERVATION; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; WOMEN'S HEALTH;

EID: 33645976475     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000194571.05427.87     Document Type: Editorial

References (22)

1. Pagnini-Hill A, Corrada M, Kawas C. Increased longevity in elderly users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause 2006;13:12-18.
2. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1776.
3. Criqui M, Suarez L, Barrett-Connor E, McPhillips J, Wingard D, Garland C. Postmenopausal estrogen use and mortality: results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128:606-614.
4. Cauley J, Seeley D, Browner W, et al. Estrogen replacement therapy and mortality among older women: the study of osteoporotic fractures. Arch Intern Med 1997;157:2181-2187.
5. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
7. Chae CU, Manson JE. Postmenopausal hormone therapy. In: Manson JE, Buring JE, Ridker PM, Gaziano JM, eds. Clinical Trials in Heart Disease, 2nd ed. Philadelphia, PA: Saunders/Elsevier, 2004:349-363.
8. Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003;10:286-291.
9. Hemelaar M, van der Mooren M, van Baal W, Schalkwijk C, Kenemans P Stehouwer C. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause 2005;12:526-535.
10. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1948-1949.
11. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
12. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
13. Allison MA, Criqui MH, Wright CM. Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:331-336.
14. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003;107:2571-2576.
15. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253-1260.
16. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-619.
17. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12.
18. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
19. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12.
20. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
21. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
22. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.